You are receiving this message as a subscriber to the FDA hepatitis electronic list serve. The purpose of the list serve is to relay important information about viral hepatitis-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.
Please do not reply to this message.
On December 18, 2013, FDA approved a new single-use, dual-chamber pre-filled pen injector, PegIntron Selectdose (peginterferon alfa-2b), with recommendations for dose reductions, an updated Medication Guide and Instructions for Use (IFU).
The full revised label, including Instructions for Use with the Selectdose single-use pre-filled pen can be found at Drugs@FDA.
Healthcare providers should show patients how to prepare and inject PegIntron properly using the Selectdose pre-filled pen before it is used for the first time. Patients should make sure they have the correct strength of Selectdose pre-filled penprescribed by their healthcare provider.
Patients should properly dispose of the pre-filled pen after use. Instructions for Disposal of used needles and pre-filled pens are provided in the "in the Instructions for Use.
Richard Klein
Office of Special Health Issues
Food and Drug Administration
Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration
If you are interested in receiving information about a broader range of FDA topics, consider subscribing to the FDA Patient Network News, a twice monthly newsletter containing FDA-related information on a variety of topics, including new product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings, proposed regulatory guidances and opportunity to comment, and other information of interest to patients and patient advocates.
This email was sent to xxxxxx@yahoo.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420
--------------------------------------
No comments:
Post a Comment